| Name | Title | Contact Details |
|---|
Sharon Care Ctr is a Centralia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medavie EMS is a health care delivery and management company based in Dartmouth, Nova Scotia, Canada. We have a team of management staff that specializes in the areas of project management, planning, education, human resources, communications finance, physical resources, process design, facilitation, reporting, and information technology. Currently, Medavie EMS is responsible to deliver EMS in Nova Scotia, New Brunswick, Prince Edward Island, the District Municipality of Muskoka in Ontario, the Municipality of Chatham-Kent in Ontario, Elgin County in Ontario, Saskatoon and surrounding areas in Saskatchewan, as well as, communities across eastern Alberta. Each of these systems is managed by subsidiary companies which have established contracts with governments (provincial and municipal) or health authorities. In addition, Medavie EMS operates a patient transfer service in Massachusetts headquartered in Boston. Combined these companies directly employ or manage a total staff of approximately 3800, 550 of whom are in the US.
Greens At Greenwich is a Greenwich, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BLOSSOM SOUTH is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.